Scaffold Hopping to Imidazo[1,2‑a]pyrazin-8-one Positive Allosteric Modulators of Metabotropic Glutamate 2 Receptor

Glutamate hyperfunction is implicated in multiple neurological and psychiatric diseases. Activation of the mGlu2 receptor results in reduced glutamate release and decreased excitability representing a promising novel therapeutic agent for the treatment of disorders such as epilepsy, schizophrenia, m...

Full description

Saved in:
Bibliographic Details
Published inACS omega Vol. 6; no. 35; pp. 22997 - 23006
Main Authors de Lucas, Ana I, Vega, Juan A, García Molina, Aránzazu, Linares, María Lourdes, Tresadern, Gary, Lavreysen, Hilde, Oehlrich, Daniel, Trabanco, Andrés A, Cid, José M
Format Journal Article
LanguageEnglish
Published American Chemical Society 07.09.2021
Online AccessGet full text

Cover

Loading…
More Information
Summary:Glutamate hyperfunction is implicated in multiple neurological and psychiatric diseases. Activation of the mGlu2 receptor results in reduced glutamate release and decreased excitability representing a promising novel therapeutic agent for the treatment of disorders such as epilepsy, schizophrenia, mood, anxiety, and other neuropsychiatric disorders. We have previously reported substantial efforts leading to potent and selective mGlu2 PAMs from different chemical series. Herein, the discovery and optimization of a novel series of imidazopyrazinone mGlu2 PAMs are reported. This new scaffold originated from computational searching of fragment databases and comparison with our previously explored scaffolds. Optimization guided by our robust understanding of SAR from former series led to potent, selective, and brain-penetrant compounds.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2470-1343
2470-1343
DOI:10.1021/acsomega.1c03739